Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: A systematic review and meta-analysis

Clinical Breast Cancer

Volumn 15, Issue 2, 2015, Pages 90-100.e1

  Kawalec, Paweł ^a   Łopuch, Sylwia ^a   Mikrut, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

First line treatment; HER2 and; HR status; Metastatic breast cancer; Systematic review and meta analysis; Targeted therapy

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; LETROZOLE; PERTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT;

BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; ADULT; BREAST NEOPLASMS; FEMALE; METASTASIS; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84924907482     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.10.006     Document Type: Review

References (56)

1. International Agency for Research on Cancer. GLOBOCAN 2012 Cancer Incidence and Mortality Worldwide. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed: February 11, 2014.
2. F. Bray, J.S. Ren, E. Masuyer, and J. Ferlay Estimates of global cancer prevalence for 27 sites in the adult population in 2008 Int J Cancer 132 2013 1133 1145
3. F. Cardoso, N. Harbeck, and L. Fallowfield Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up Ann Oncol 23 2012 11 19
4. F.A. Tavassoeli, and P. Devilee Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours 2003 IARC, WHO Press Lyon, France 9 110
5. S.B. Edge, D.R. Byrd, and C.C. Compton Breast S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti, AJCC Cancer Staging Manual 7th ed 2010 Springer New York, NY 347 376
6. C.M. Perou, T. Sørlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
7. T. Sørlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
8. F. Cardoso, A. Costa, and L. Norton 1st international consensus guidelines for advanced breast cancer (ABC1) Breast 21 2012 242 252
9. T. Fojo, and D.R. Parkinson Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much Clin Cancer Res 16 2010 5972 5980
10. L.J. van't Veer, and R. Bernards Enabling personalized cancer medicine through analysis of gene-expression patterns Nature 452 2008 564 570
11. European Medicine Agency Web site. Available at: http://www.ema.europa.eu. Accessed: February 11, 2014.
12. Food and Drug Administration. Available at: http://www.fda.gov. Accessed: February 11, 2014.
13. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N Engl J Med 357 2007 39 51
14. G. Valabrega, F. Montemurro, and M. Aglietta Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 2007 977 984
15. M. Hubalek, C. Brantner, and C. Marth Role of pertuzumab in the treatment of HER2-positive breast cancer Breast Cancer (Dove Med Press) 4 2012 65 73
16. P.M. LoRusso, D. Weiss, and E. Guardino Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin Cancer Res 17 2011 6437 6447
17. L.M. Ellis Mechanisms of action of bevacizumab as component of therapy for metastatic colorectal cancer Semin Oncol 33 2006 S1 7
18. M. Untch, and H.J. Luck Lapatinib - member of a new generation of ErbB-targeting drugs Breast Care 5 2010 8 12
19. P.J. Houghton Everolimus Clin Cancer Res 16 2010 1368 1372
20. B. Escudier, and J.A. Thompson Mechanism of action of everolimus in renal cell carcinoma Med Oncol 26 2009 S32 S39
21. A.A. Ontilio, J.M. Engel, R.T. Greenlee, and B.N. Mukesh Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival Clin Med Res 7 2009 4 13
22. T.H.M. Keegan, M.C. DeRouen, and D.J. Press Occurrence of breast cancer subtypes in adolescent and young adult women Breast Cancer Res 14 2012 R55 63
23. K.D. Voduc, M.C.U. Cheang, and S. Tyldesley Breast cancer subtypes and the risk of local and regional relapse J Clin Oncol 28 2010 1684 1691
24. R. Nahta Molecular mechanisms of trastuzumab-based treatment in HER2-ovserexpressing breast cancer ISRN Oncol 2012 2012 428062
25. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
26. D. Moher, A. Liberati, and J. Tetzlaff Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement BMJ 339 2009 332 336
27. J.P.T. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011] 2011 The Cochrane Collaboration Available at: www.cochrane-handbook.org Accessed: February 11, 2014
28. G. Gasparini, M. Gion, and L. Mariani Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer Breast Cancer Res Treat 101 2007 355 365
29. M. Marty, F. Cognetti, and D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 2005 4265 4274
30. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
31. J. Huober, P.A. Fasching, and M. Barsoum Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2+, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial Breast 21 2012 27 33
32. B. Kaufman, J.R. Mackey, and M.R. Clemens Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 2009 5529 5537
33. J. Baselga, J. Cortés, and S.B. Kim Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
34. S.M. Swain, S.B. Kim, and J. Cortés Pertuzumab, trastuzumab, and docetaxel for HER2+ metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 2013 461 471
35. A. Di Leo, H.L. Gomez, and Z. Aziz Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J Clin Oncol 26 2008 5544 5552
36. L.S. Schwartzberg, S.X. Franco, and A. Florance Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer Oncologist 15 2010 122 129
37. S. Johnston, J. Pippen Jr., and X. Pivot Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 2009 5538 5546
38. Z. Guan, B. Xu, and M.L. DeSilvio Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2 - overexpressing metastatic breast cancer J Clin Oncol 31 2013 1947 1953
39. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
40. D.W. Miles, A. Chan, and L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
41. N.J. Robert, V. Diéras, and J. Glaspy RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
42. L. Gianni, G.H. Romieu, and M. Lichinitser AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2+ locally recurrent/metastatic breast cancer J Clin Oncol 31 2013 1719 1725
43. C.A. Harris, R.L. Ward, and T.A. Dobbins The efficacy of HER2-targeted therapy agents in metastatic breast cancer: a meta-analysis Ann Oncol 22 2011 1308 1317
44. J.R. Rossari, O. Metzger-Filho, and M. Paesmans Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence J Oncol 2012 2012 417673
45. S.R. Johnston The role of chemotherapy and targeted agents in patients with metastatic breast cancer Eur J Cancer 47 2011 38 47
46. A.L. Schechter, D.F. Stern, and L. Vaidyanathan The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 312 1984 513 516
47. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene Science 235 1987 177 182
48. M.M. Moasser The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis Oncogene 26 2007 6469 6487
49. W. Dean-Colomb, and F.J. Esteva Her2-positive breast cancer: Herceptin and beyond Eur J Cancer 44 2008 2806 2812
50. J. Baselaga, M. Campone, and M. Piccart Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
51. G.J. Sabinis, D. Jelovac, B. Long, and A. Brodie The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation Cancer Res 65 2005 3903 3910
52. Y.C. Wang, G. Morris, and R. Gillihan Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-posistive breast cancers - role of estrogen receptor and HER reactivation Breast Cancer Res 13 2011 R121 R139
53. J. Shou, S. Massarweh, and C.K. Osborne Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2+ breast cancer J Natl Cancer Inst 96 2004 925 956
54. A. Prat, and J. Baselaga The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Oncology 5 2008 531 542
55. P. Lal, L.K. Tan, and B. Chen Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas Am J Clin Pathol 125 2005 541 546
56. A. Brufsky, B. Lembersky, and K. Schiffman Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer Clin Breast Cancer 6 2005 247 252